Genmark Diagnostics (GNMK) Stock Price
Genmark Diagnostics Price
Revenue has compounded at 59.2% per year over the past 12 years to 171.55 M USD. Genmark Diagnostics's net margin stands at -10.9%, up from -102.7% several years earlier.
Genmark Diagnostics stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Genmark Diagnostics business model & stock analysis
Frequently asked questions about Genmark Diagnostics
Genmark Diagnostics Inc. operates with a business model focused on developing molecular diagnostic solutions. The company primarily specializes in the design, manufacturing, and marketing of diagnostic testing systems. Genmark's products are engineered to deliver accurate and timely results for detecting various infectious diseases and genetic conditions. Their solutions are designed to be flexible, providing rapid and comprehensive testing capabilities for a wide range of clinical applications. With a strong emphasis on innovation and advanced technology, Genmark Diagnostics Inc. aims to provide healthcare professionals with the tools they need to enhance patient care and improve overall outcomes.
Genmark Diagnostics Inc is primarily active in the healthcare and life sciences industries.
The main competitors of Genmark Diagnostics Inc in the market include Abbott Laboratories, Bio-Rad Laboratories, Danaher Corporation, and Roche Holding AG.
Genmark Diagnostics Inc, founded in 1993, is a leading provider of molecular diagnostic solutions. It specializes in developing and commercializing multiplex molecular tests, automation platforms, and software analytics. The company's innovative solutions enable healthcare providers to quickly and accurately diagnose multiple diseases, including respiratory infections, gastrointestinal infections, and sepsis. Genmark Diagnostics Inc has a strong track record of delivering high-quality testing solutions, enabling hospitals and laboratories to improve patient care and outcomes. With a dedicated team and a commitment to advancing molecular diagnostics, Genmark Diagnostics Inc continues to drive innovation and shape the future of diagnostic testing.
Genmark Diagnostics Inc has achieved several significant milestones. The company has consistently demonstrated its commitment to innovation and excellence in the field of molecular diagnostics. Notably, Genmark Diagnostics Inc received FDA clearance for its ePlex® Blood Culture Identification Gram-Negative (BCID-GN) Panel, offering rapid and accurate identification of bloodstream infections caused by gram-negative bacteria. In addition, the company has successfully expanded its global presence by obtaining regulatory approvals and entering strategic partnerships in various regions. Genmark Diagnostics Inc has also received recognition for its pioneering technologies and has been honored with prestigious industry awards. These achievements showcase the company's dedication to transforming patient care through cutting-edge diagnostic solutions.
Genmark Diagnostics Inc is primarily present in the United States.
Genmark Diagnostics Inc represents values of innovation, quality, and commitment to improving healthcare. With a strong corporate philosophy focused on developing and delivering high-impact molecular diagnostic solutions, Genmark aims to address critical testing needs in the healthcare industry. By leveraging advanced technologies and expertise, the company strives to enhance patient care through accurate and timely diagnostics. Genmark Diagnostics Inc's dedication to driving meaningful advancements in molecular testing and improving patient outcomes stands as a testament to their commitment to excellence in the field of diagnostic medicine.
Genmark Diagnostics Inc is a leading company in molecular diagnostics that offers innovative solutions for healthcare. The company was founded in 1993 and is headquartered in Carlsbad, California. Genmark specializes in the development of molecular diagnostic devices and test kits for medical diagnostics. Its business model includes the sale of diagnostic devices, development and sale of test kits, and diagnostic-related services. Genmark offers two diagnostic systems, the XT-8 and ePlex, which provide fast and accurate diagnosis of infectious diseases and genetic mutations. In addition, the company offers a wide range of test kits for various infections and provides diagnostic services such as clinical consultation and training. Genmark is also actively involved in research and development of new diagnostic devices and test kits tailored to customer and patient needs. Overall, the company aims to offer innovative solutions and services in healthcare, focusing on rapid and accurate diagnosis of infections and genetic mutations.
The revenue cannot currently be calculated for Genmark Diagnostics.
The profit cannot currently be calculated for Genmark Diagnostics.
The P/E ratio cannot be calculated for Genmark Diagnostics at the moment.
The P/S cannot be calculated for Genmark Diagnostics currently.
The Eulerpool Quality Score for Genmark Diagnostics is 4/10.
The ISIN of Genmark Diagnostics is US3723091043. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Genmark Diagnostics is A1CVZA. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Genmark Diagnostics is GNMK. The ticker symbol is used to trade Genmark Diagnostics shares on the stock exchange.
Genmark Diagnostics stock
Genmark Diagnostics Peer Group
Genmark Diagnostics FIGI
All fundamentals and in-depth analysis of Genmark Diagnostics
Our stock analysis for Genmark Diagnostics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genmark Diagnostics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.